Epclusa: Clinical Trials

12 trials of Epclusa, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown, 3 completed, 2 active not recruiting, 2 terminated. 12 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 412Unknown 4, Completed 3, Active not recruiting 2, Terminated 2, Withdrawn 1

Follow Epclusa: new trials by email Literature Review of Epclusa trials Research Report on Epclusa

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis
Phase 4UnknownPeking University People's Hospital1002022-09-012022-07-21
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection
Phase 4Active not recruitingCatherine Anne Chappell1002022-04-042026-10-19
Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir - Hepatitis C, Chronic
Phase 4UnknownPartners in Health1002019-08-262019-09-11
HCV Post-Exposure Prophylaxis for Health Care Workers
Sofosbuvir/Velpatasvir Treatment for 14 days - Hepatitis C
Phase 4WithdrawnMassachusetts General Hospital2019-08-132020-01-21
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks - Respiratory Failure, Hepatitis C
Phase 4TerminatedMassachusetts General Hospital192019-02-052023-04-25
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy - Hepatitis C, HIV-1-infection
Phase 4CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections4002018-10-222022-02-04
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Epclusa - Diabetes Mellitus, Hepatitis C, Chronic
Phase 4Active not recruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1212018-10-192026-10-22
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Genvoya, Epclusa, Biktarvy - HIV-1-infection, Hepatitis C, Chronic
Phase 4UnknownSaskatchewan Health Authority - Regina Area252018-02-012019-12-24
Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
Sofosbuvir/Velpatasvir - Hepatitis C, Chronic, Opioid-use Disorder
Phase 4CompletedElizabeth Krans, MD322018-01-302023-05-06
Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment
Epclusa - Hepatitis C, Chronic, Lung Transplant
Phase 4TerminatedDuke University12017-09-152019-09-11
Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial
sofosbuvir/velpatasvir - Thalassemia, Hepatitis C
Phase 4CompletedAla'a Sharara72017-05-012018-10-11
Transplanting Hepatitis C Positive Organs
Sofosbuvir/velpatasvir, Monitoring - Hepatitis C, Awaiting Organ Transplant
Phase 4UnknownBrigham and Women's Hospital1482017-03-012022-10-12

Conditions studied

Hepatitis C (9)  ·  Hepatitis C, Chronic (6)  ·  Fibrosis (2)  ·  Opioid-Related Disorders (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Bone Diseases, Metabolic (1)  ·  Carcinoma, Hepatocellular (1)  ·  Cardiovascular Diseases (1)  ·  Coinfection (1)  ·  Diabetes Mellitus (1)  ·  Liver Diseases (1)  ·  Lung Diseases (1)  ·  Needlestick Injuries (1)  ·  Pregnancy Complications, Infectious (1)  ·  Respiratory Insufficiency (1)

Sponsors

Massachusetts General Hospital (2)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)  ·  Ala'a Sharara (1)  ·  Brigham and Women's Hospital (1)  ·  Catherine Anne Chappell (1)  ·  Duke University (1)  ·  Elizabeth Krans, MD (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Partners in Health (1)  ·  Peking University People's Hospital (1)  ·  Saskatchewan Health Authority - Regina Area (1)

Countries

United States (8)  ·  Canada (2)  ·  Brazil (1)  ·  Lebanon (1)  ·  Puerto Rico (1)  ·  Rwanda (1)  ·  South Africa (1)  ·  Thailand (1)  ·  Uganda (1)

Top investigators

Alexander Wong, MD (1)  ·  Catherine Chappell, MD, MSc (1)  ·  Elizabeth E Krans, MD, MSc (1)  ·  Fredrick Kateera, MD, PhD (1)  ·  Huiying Rao, Dr. (1)  ·  Lindsey Baden, MD (1)  ·  Marc G Ghany, M.D. (1)  ·  Neil Gupta, MD, MPH (1)  ·  Omar Mohamedaly, MD (1)  ·  Raymond Chung, MD (1)  ·  Raymond T Chung, MD (1)  ·  Sunil Solomon, MBBS, PhD, MPH (1)

Results publications

PMID 30552056, PMID 30946553, PMID 35026142, PMID 35248212, PMID 35248213, PMID 36694361, PMID 39702964, PMID 40019678, PMID 41255102

NIH funding

UM1AI068636 (1)